Pfizer (PFE 0.74%) stock hasn't made for a good investment over the past five years. It has declined by 25% in value over ...
Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an ...
They aren't just "pandemic stocks." ...
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...
About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, ...
Pfizer is betting on a new breast cancer drug combo that, in a key mid-stage trial, cut the risk of the disease worsening or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results